SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

US FDA issues import alert for Wockhardt’s Chikalthana facility at Aurangabad

27 Nov 2013 Evaluate

US Food and Drug Administration (US FDA) has imposed an import alert for the drug maker Wockhardt’s Chikalthana facility at Aurangabad. An import alert results in the detention without physical examination of drugs from firms that have not met so-called good manufacturing practices.

Meanwhile, the company dropped from the Morgan Stanley Capital International (MSCI) India index with effect from November 26, 2013. MSCI is a leading provider of benchmark indices globally.

Wockhardt is one of the few companies with end to end integrated capabilities for its products, starting with the manufacture of the oral and sterile API’s, the dose forms and marketing through wholly owned subsidiary in the US, enabling the company to capture maximum value.

Wockhardt Share Price

1606.90 -29.85 (-1.82%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×